Gyre Therapeutics, Inc.GYRENASDAQ
Loading
EBITDA as a percentage of revenue
3Y CAGR
+7.7%/yr
Annual compound
Percentile
P86
Within normal range
vs 3Y Ago
1.2x
Modest growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | 12.62% | -25.1% |
| 2024 | 16.85% | -6.0% |
| 2023 | 17.92% | +77.4% |
| 2022 | 10.10% | +100.8% |
| 2021 | -1194.37% | -346.0% |
| 2020 | -267.82% | - |
| 2019 | 0.00% | +100.0% |
| 2018 | -563700.00% | -26196.7% |
| 2017 | -2143.61% | +49.5% |
| 2016 | -4246.87% | - |